Qianjiang Yongan Pharmaceutical Co., Ltd.
Simbol: 002365.SZ
SHZ
8.24
CNYTržna cena danes
1753.8874
Razmerje P/E
28.8139
Razmerje PEG
2.43B
Kapaciteta MRK
- 0.01%
Donos DIV
Qianjiang Yongan Pharmaceutical Co., Ltd. (002365-SZ) Finančni izkazi
Bilanca stanja
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 3696.04 | 956.5 | 832.2 | 547.5 | ||||||||||||||||||
balance-sheet.row.short-term-investments | 2581.9 | 630.4 | 557.5 | 454 | ||||||||||||||||||
balance-sheet.row.net-receivables | 794.98 | 178.4 | 203.1 | 367.8 | ||||||||||||||||||
balance-sheet.row.inventory | 310.95 | 69.9 | 149.6 | 145.8 | ||||||||||||||||||
balance-sheet.row.other-current-assets | 21.25 | 8.8 | 10.4 | 4.8 | ||||||||||||||||||
balance-sheet.row.total-current-assets | 4823.23 | 1213.6 | 1195.3 | 1065.9 | ||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 3948.37 | 970.9 | 1023.5 | 989.3 | ||||||||||||||||||
balance-sheet.row.goodwill | 18.57 | 0.5 | 8.8 | 8.8 | ||||||||||||||||||
balance-sheet.row.intangible-assets | 331.84 | 82.4 | 84.5 | 87.9 | ||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 350.41 | 82.9 | 93.3 | 96.7 | ||||||||||||||||||
balance-sheet.row.long-term-investments | -926.92 | 68.3 | -476.1 | -338.8 | ||||||||||||||||||
balance-sheet.row.tax-assets | 40.83 | 11.3 | 9.7 | 9.9 | ||||||||||||||||||
balance-sheet.row.other-non-current-assets | 1311.93 | 0.1 | 578.5 | 462.9 | ||||||||||||||||||
balance-sheet.row.total-non-current-assets | 4724.61 | 1133.5 | 1228.8 | 1220 | ||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.total-assets | 9547.85 | 2347.1 | 2424.2 | 2285.9 | ||||||||||||||||||
balance-sheet.row.account-payables | 542.02 | 128.8 | 162.8 | 114.9 | ||||||||||||||||||
balance-sheet.row.short-term-debt | 93.03 | 47.3 | 40 | 20.4 | ||||||||||||||||||
balance-sheet.row.tax-payables | 56.99 | 7.8 | 4.9 | 5.5 | ||||||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 0 | 0 | 0 | ||||||||||||||||||
Deferred Revenue Non Current | 35.42 | 8.5 | 11.3 | 13.1 | ||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 114.65 | - | - | - | ||||||||||||||||||
balance-sheet.row.other-current-liab | 161.86 | 65.6 | 70.6 | 78.5 | ||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 141.57 | 33.1 | 36 | 35.6 | ||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.total-liab | 1163.17 | 290.3 | 321.2 | 328.9 | ||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.common-stock | 1178.73 | 294.7 | 294.7 | 294.7 | ||||||||||||||||||
balance-sheet.row.retained-earnings | 3406.61 | 812.7 | 854.5 | 728.2 | ||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 2079.42 | 163.8 | 155.4 | 130.9 | ||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 1425.56 | 712.8 | 712.8 | 712.2 | ||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 8090.32 | 1983.9 | 2017.4 | 1865.9 | ||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 9547.85 | 2347.1 | 2424.2 | 2285.9 | ||||||||||||||||||
balance-sheet.row.minority-interest | 285.85 | 64.4 | 85.6 | 91.1 | ||||||||||||||||||
balance-sheet.row.total-equity | 8376.17 | 2048.3 | 2103 | 1957 | ||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 9547.85 | - | - | - | ||||||||||||||||||
Total Investments | 1654.98 | 698.7 | 81.4 | 115.2 | ||||||||||||||||||
balance-sheet.row.total-debt | 93.03 | 47.3 | 40 | 20.4 | ||||||||||||||||||
balance-sheet.row.net-debt | -1021.1 | -278.9 | -234.7 | -73.1 |
Izkaz denarnih tokov
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 1.38 | -12.3 | 132.7 | 119 | ||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0.09 | 135.2 | 123.6 | 116 | ||||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 6.8 | 2.4 | -3.8 | ||||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | -176.9 | 0.9 | 12.4 | ||||||||||||||||||
cash-flows.row.change-in-working-capital | 106.58 | 93.5 | 99.1 | -152.4 | ||||||||||||||||||
cash-flows.row.account-receivables | 18.85 | 18.9 | 163.2 | -172.1 | ||||||||||||||||||
cash-flows.row.inventory | 87.73 | 87.7 | -10 | -63.7 | ||||||||||||||||||
cash-flows.row.account-payables | 0 | -13.1 | -56.5 | 87.2 | ||||||||||||||||||
cash-flows.row.other-working-capital | 0 | 0 | 2.4 | -3.8 | ||||||||||||||||||
cash-flows.row.other-non-cash-items | 71.81 | 197.9 | 28.5 | 10.7 | ||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 179.87 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -119.09 | -120.7 | -149.1 | -63 | ||||||||||||||||||
cash-flows.row.acquisitions-net | 0.87 | 1 | 0.4 | -35.9 | ||||||||||||||||||
cash-flows.row.purchases-of-investments | -1350.13 | -1484.2 | -1110.7 | -823.2 | ||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 1299.19 | 1392.7 | 1029 | 943.5 | ||||||||||||||||||
cash-flows.row.other-investing-activites | 22.57 | 45.2 | 0 | 0.5 | ||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -123.95 | -166 | -230.4 | 21.8 | ||||||||||||||||||
cash-flows.row.debt-repayment | -10.6 | -30 | -40 | -132.3 | ||||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.dividends-paid | -44.62 | -29.5 | -1.6 | -30.7 | ||||||||||||||||||
cash-flows.row.other-financing-activites | -2.27 | -6.3 | 59.4 | 23.8 | ||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -41.19 | -65.8 | 17.8 | -139.2 | ||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 10.45 | 7.1 | 6.5 | -1.1 | ||||||||||||||||||
cash-flows.row.net-change-in-cash | 9.69 | 51.5 | 181.2 | -16.7 | ||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 1070.94 | 326.2 | 274.7 | 93.5 | ||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 1061.25 | 274.7 | 93.5 | 110.2 | ||||||||||||||||||
cash-flows.row.operating-cash-flow | 179.87 | 244.3 | 387.3 | 101.8 | ||||||||||||||||||
cash-flows.row.capital-expenditure | -119.09 | -120.7 | -149.1 | -63 | ||||||||||||||||||
cash-flows.row.free-cash-flow | 60.78 | 123.5 | 238.2 | 38.8 |
Vrstica izkaza poslovnega izida
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 852.45 | 962.8 | 1462.4 | 1565.4 | ||||||||||||||||||
income-statement-row.row.cost-of-revenue | 643.48 | 733.5 | 980.8 | 1206.9 | ||||||||||||||||||
income-statement-row.row.gross-profit | 208.97 | 229.3 | 481.7 | 358.5 | ||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||||
income-statement-row.row.research-development | 41.02 | - | - | - | ||||||||||||||||||
income-statement-row.row.selling-general-administrative | 73.14 | - | - | - | ||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 18.03 | - | - | - | ||||||||||||||||||
income-statement-row.row.other-expenses | -94.9 | -1.2 | 66.2 | 69.7 | ||||||||||||||||||
income-statement-row.row.operating-expenses | 280.6 | 205 | 320.3 | 228.6 | ||||||||||||||||||
income-statement-row.row.cost-and-expenses | 924.08 | 938.5 | 1301.1 | 1435.4 | ||||||||||||||||||
income-statement-row.row.interest-income | 1.56 | 1.9 | 0.3 | 0.2 | ||||||||||||||||||
income-statement-row.row.interest-expense | 0.4 | 0.4 | 0.7 | 2.4 | ||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 18.03 | - | - | - | ||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 66.41 | -20.9 | 0.7 | -1.8 | ||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||||
income-statement-row.row.other-operating-expenses | -94.9 | -1.2 | 66.2 | 69.7 | ||||||||||||||||||
income-statement-row.row.total-operating-expenses | 66.41 | -20.9 | 0.7 | -1.8 | ||||||||||||||||||
income-statement-row.row.interest-expense | 0.4 | 0.4 | 0.7 | 2.4 | ||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 59.89 | 135.2 | 167.1 | 132.3 | ||||||||||||||||||
income-statement-row.row.ebitda-caps | -1.6 | - | - | - | ||||||||||||||||||
income-statement-row.row.operating-income | -43.84 | 24.3 | 152.4 | 131.7 | ||||||||||||||||||
income-statement-row.row.income-before-tax | 22.57 | 3.4 | 153.1 | 129.9 | ||||||||||||||||||
income-statement-row.row.income-tax-expense | 38.46 | 34.5 | 20.3 | 10.8 | ||||||||||||||||||
income-statement-row.row.net-income | 1.38 | -12.3 | 140.3 | 111.4 |
Pogosto zastavljeno vprašanje
Kaj je Qianjiang Yongan Pharmaceutical Co., Ltd. (002365.SZ) skupna sredstva?
Qianjiang Yongan Pharmaceutical Co., Ltd. (002365.SZ) skupna sredstva so 2347138093.000.
Kakšen je letni prihodek podjetja?
Letni prihodki so 360799673.000.
Kolikšna je stopnja dobička podjetja?
Dobiček podjetja je 0.245.
Kakšen je prosti denarni tok podjetja?
Prosti denarni tok je 0.206.
Kolikšna je neto stopnja dobička podjetja?
Čista stopnja dobička je 0.002.
Kolikšni so skupni prihodki podjetja?
Celotni prihodki so -0.051.
Kaj je Qianjiang Yongan Pharmaceutical Co., Ltd. (002365.SZ) čisti dobiček (čisti dobiček)?
Čisti dobiček (čisti prihodek) je -12312563.000.
Kolikšen je skupni dolg podjetja?
Skupni dolg je 47305897.000.
Kolikšni so stroški poslovanja?
Stroški poslovanja so 205002116.000.
Kolikšno je število denarnih sredstev podjetja?
Denarna sredstva podjetja so 244645727.000.